Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer

a technology of nutrient pharmaceutical formulation and polyphenol, which is applied in the direction of biocide, drug composition, peptide/protein ingredients, etc., can solve the problems of inability to control cancer metastasis, inability to use specific drugs, and severe side effects, and achieve the effect of inhibiting the expression of mmp-2

Inactive Publication Date: 2006-06-29
NETKE SHRIRANG +3
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] In one object, the present invention provides a nutrient pharmaceutical composition useful in treating cancer, comprising: a) an ascorbic compound, b) a L-lysine compound, c) a L-proline compound, and d) at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, and catechin. Compounds of a-c) enhance the polyphenol compound's activity in blocking cancer proliferation and metastasis.
[0014] In another object, the present invention provides a nutrient pharmaceutical composition useful in treating cancer, comprising: a) an ascorbic compound, b) a L-lysine compound, c) a L-proline compound, d) N-acetyl cysteine, and e) at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, and catechin. The a-d) compounds enhance the polyphenol compound's activity in blocking cancer proliferation and metastasis.

Problems solved by technology

The most widely used treatments—chemotherapy and radiotherapy—do not distinguish between healthy tissue and cancer and are associated with severe side effects.
Therapeutic approaches to control this process through specific drugs have not been successful and currently there are no means available to control cancer metastasis.
Current treatment protocols with chemotherapy and radio-therapy focus on cancer cell destruction in the body, and they do not address metastasis.
Moreover, these treatments are toxic, not specific and associated with severe side effects.
Chemotherapy and radio-therapy carry a risk of the development of new cancers and through their destruction of connective tissue in the body can facilitate the invasion of cancer.
Given the fact that the bioavailability of polyphenols in humans is extremely low, the low tissue concentration of catechins greatly reduces the therapeutic value of polyphenols including epigallocatechin gallate (EGCG).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
  • Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
  • Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0071] MDA-MB 231 (ATCC) breast cancer cells were seeded on Matrigel insert in an improved Matrigel Invasion Chamber (BD). Conditioned media from normal human dermal fibroblast (Clonetics) supplemented with various agents (as indicated on FIG. 1) were added to the well. The chamber was incubated for 24 hours and the cells that had invaded the Matrigel membrane and had migrated into the lower surface of the membrane were counted. These data show the inhibitory effect of epigallocatechin gallate and the combination of ascorbic acid, proline and lysine on Matrigel invasion and migration by MDA-MB 231 human breast cancer cells. These data also show that the combined effects of ascorbic acid, proline and lysine in enhancing the anti-cancer activity of epigallocatechin gallate.

example 2

[0072] HTCT116 (ATCC) human colon cancer cells were seeded on Matrigel insert in an improved Matrigel Invasion Chamber (BD). Conditioned media from Normal Human Dermal Fibroblast (Clonetics) supplemented with various agents (as indicated on FIG. 2) were added to the well. The chamber was incubated for 24 hours and the cells that had invaded the Matrigel membrane and had migrated into the lower surface of the membrane were counted. These data show an inhibitory effect of epigallocatechin gallate and the combination of ascorbic acid, proline and lysine on Matrigel invasion and migration by HCT116 human colon cancer cells. These data also show that the combined effects of ascorbic acid, proline and lysine in enhancing the anti-cancer activity of epigallocatechin gallate.

example 3

[0073] A2058 (ATCC) human melanoma cells were seeded on Matrigel insert in improved Matrigel Invasion Chamber (BD). Conditioned media from Normal Human Dermal Fibroblast (Clonetics) supplemented with various agents was added to the well. The chamber was incubated for 24 hours and the cells that had invaded the Matrigel membrane and had migrated into the lower surface of the membrane were counted. These data show an inhibitory effect of epigallocatechin gallate and the combination of ascorbic acid, proline and lysine on Matrigel invasion and migration by A2058 human melanoma cells. These data also show that the combined effects of ascorbic acid, proline and lysine in enhancing the anti-cancer activity of epigallocatechin gallate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

A nutrient pharmaceutical formulation composition useful for treating cancer comprising ascorbic acid, L-lysine, L-proline and at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, catechin and the use of the composition in treating cancer and other tumors are provided. A nutrient pharmaceutical formulation composition of EPICAN FORTE™ and its method of use in treating cancer are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application Ser. No. 60 / 348,143 filed Jan. 11, 2002, the content of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to a nutrient pharmaceutical formulation and its use for the treatment of cancer. More specifically, the present invention relates to polyphenol containing pharmaceutical formulations having an effective amount of polyphenols for the treatment of cancer. The formulation of the present invention is used as an agent for the prevention and treatment of cancer comprising ascorbic acid, lysine, proline and at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, and catechin. BACKGROUND OF THE INVENTION [0003] Cancer is one of the leading causes of death in the industrialized world. There e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7048A61K31/401A61K31/375A61K31/353A61K31/198A61K31/00A23L1/30A23L1/304A23L1/305A61K31/195A61K33/04A61K33/06A61K33/32A61K33/34A61K45/06A61P19/02A61P29/00A61P35/00A61P43/00
CPCA23L1/3002A23L1/304A23L1/3051A23V2002/00A61K31/195A61K31/353A61K31/375A61K45/06A61K2300/00A23V2250/708A23V2250/063A23V2250/064A23V2250/2132A23V2250/1578A23V2250/161A23V2250/214A23V2250/0616A23L33/105A23L33/16A23L33/175A61P19/02A61P29/00A61P35/00A61P43/00A61K31/401
Inventor NETKE, SHRIRANGNIEDZWIECKI, ALEKSANDRARATH, MATTHIASROOMI, WAHEED M.
Owner NETKE SHRIRANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com